Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$273,359.00
Oct 1, 2012
HPV Vaccination Discourses, Practices and Spaces: Affects and Effects on Youth's Bodies and Subjectivities
$2,864,660.00
Oct 1, 2012
A Randomized Controlled Trial of Live Attenuated Vaccine versus Trivalent Inactivated Vaccine in Hutterite Children
$105,000.00
Sep 1, 2012
Development of personalized vaccines targeting tumour-specific mutations
$135,000.00
Jul 1, 2012
Generation of a dendritic cell-based vaccine by modulating the expression of protein tyrosine phosphatases.
$105,000.00
May 1, 2012
The examination of a novel viral vector and immunogens for HIV/SIV vaccine development in a non-human primate model
$105,000.00
May 1, 2012
Determining the Risk of Adverse Events following Recommended Pediatric Vaccinations in the General Population and Vulnerable Subgroups of Children in Ontario, Canada
$789,160.00
Apr 1, 2012
Development of small molecule viral sensitizers to boost vaccine manufacturing
$743,020.00
Apr 1, 2012
Investigation of broadly cross-protective antibodies against influenza hemagglutinin and the development of better influenza vaccines
$150,000.00
Apr 1, 2012
Characterization of human cytotolytic T lymphocyte polyfunctionality and clonality in vaccinated melanoma patients at the single-cell level.
$116,317.00
Apr 1, 2012
Diabetes, influenza, and cardiopulmonary outcomes: The rationale for targeting influenza vaccinations for patients with diabetes